Overweight and Obesity
Conditions
Brief summary
Impaired glucose regulation (IGR) is closely related to overweight/obesity. By studying different dietary patterns (energy-limited diet vs. low-carbohydrate diet) and intensive lifestyle interventions combined with blood glucose monitoring, glucose regulation of overweight/obesity is affected. To improve the blood glucose and related metabolic indexes of patients with impaired (IGR), establish 1-2 clinical intervention programs for impaired glucose regulation.
Interventions
DIETARY_SUPPLEMENTLow fat diet intensive intervention
education and Compound protein solid beverage
OTHERLow-Carbon Water Diet Intensive Intervention
education and Nutrition bar
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18-65 years old ② Fasting blood glucose is between 5.6-6.9 mmol/L (100-125mg/dL) or oral glucose tolerance test (OGTT) 2h plasma glucose (2h-PG) is 7.8-11.1 mmol/L (140-200 mg/dL) * 24 kg/m2 ≤ BMI ≤ 35 kg/m2 * Those who are willing to accept assessment and sign informed consent.
Exclusion criteria
* Patients diagnosed with diabetes or undergoing diabetes treatment; * Receiving drugs or surgery for weight loss at present or in the past 3 months; * Receiving corticosteroid or thyroid hormone treatment; * Secondary obesity caused by endocrine, genetic, metabolic and central nervous system diseases; * Patients with abnormal liver function (alanine aminotransferase or/and aspartate aminotransferase exceeding the upper limit of normal value 3 times); patients with abnormal renal function (serum creatinine exceeding the upper limit of normal value); suffering from kidney disease and other diseases that need to control protein intake; * Diseases affecting the digestion and absorption of food (such as chronic diarrhea, constipation, severe gastrointestinal inflammation, active gastrointestinal ulcer, gastrointestinal resection, cholecystitis/cholecystectomy, etc.); ⑦ Suffering from cardiovascular and cerebrovascular diseases, grade 3 hypertension, chronic hepatitis, malignant tumors, anemia, mental illness and memory disorders, epilepsy and other diseases; ⑧ Suffering from infectious diseases such as active tuberculosis and AIDS; ⑨ During pregnancy or lactation; ⑩Patients with physical disabilities and clinicians think it is not suitable to participate in the study (for example, have a serious disease not included in the discharge criteria) or are unwilling to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood glucose | ten weeks |
| Blood glucose 2 hours after meal | ten weeks |
Countries
China
Outcome results
None listed